Top ideas at Singular Research summer solstice conference in Boston July 13
Featuring undervalued and undercovered and small-cap stocks. Our conferences are not your typical dog and pony show or investment banking round up. We focus on best ideas that are performance-based under covered and misunderstood by the street.
We look to spotlight some of our most compelling ideas at our conferences each and every year throughout the United States. Our coverage list has provided an unmatched performance beating the competition and the market indexes by wide and consistent margin over the last 12 years.
Our conference is heavy on healthcare and Biotech ideas, two sectors that have Lagged the market in 2017. We are featuring some compelling names in these sectors that are also under owned by institutions and under covered by Wall Street research. We invite encourage you to join us on our webcast by clicking the link below.
Here are a few ideas we will be featuring.
Aceto Corporation (ACET): recent price $15 12 month target $29
Up 124% since we launched coverage . Aceto is off nearly 50% from its December 2015 high where Managment issued over $400 million in debt and equity to make a synergistic and game changing acquisitions. While sales and earnings has disappointed the company is assimilating its large acquisition of Citron /Lucid , we expect ACET to resume an upward ramp in late 2017 and into 2018 , driven by the expected launch of 27-30 new products as this emerging leader in finished dosage generics and human health products should provide significant upside returns for patient Investor's.
Anika Therapeutics (ANIK) Recent price $49.50 12 meters month target $60
Since we initiated coverage about five years ago , ANIK has been one of our greatest picks , up over 270%. This innovator of therapeutic products for tissue protection utilizes hyaluronic acid and is a great friend of the aging baby boomers providing relief from osteoarthritis and back , knee and hip ailments. This run up was driven largely by his flagship product Monovisc . The stock is been pacing for about two years while it's next stage products are in development. Monovisc , could have greater upside. it is a one treatment process, as opposed to the three treatment products in the market , providing The dual benefit of greater efficacy with less pain. Other products are anticipated to hit the market from late 2018 through 2020. Management currently projects the addressable market for products available and in development could approach $4 billion.
Boston Summer Solstice Conference
July 13th, 2017
Metro Meeting Centers
101 Federal Street, 4th Floor
Boston, MA 02110
Click Below for Summer Solstice Boston 2017 Registration & 1-1 Meeting Requests
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.